EnteroBiotix Expands Headcount and Premises to Advance Microbiome Drug Pipeline
Glasgow, Scotland – 27 October 2021 – EnteroBiotix, a biopharmaceutical company developing novel highly-diverse microbial therapeutics that enhance the gut microbiome, today announced the mechanical completion of a new purpose built world-class facility at Strathclyde Business Park, Glasgow, for manufacturing and quality control of its high-diversity microbial therapeutics, and an expansion of its corporate offices to support an increased headcount. This expansion follows the company’s successful $21.5M Series A fundraising announced in September.
EnteroBiotix’s new footprint is set to expand to over 20,000 square feet and is based in Scotland’s notable Strathclyde Business Park. This new manufacturing facility is believed to be the most advanced of its kind in Europe and is designed to be in line with key regulatory requirements for advanced biologics production and analytical activities. The new facility will underpin the Company’s therapeutic pipeline, providing end-to-end control of the supply chain. It also provides capabilities that can be leveraged by partners. In addition to advancing its product pipeline, EnteroBiotix plans to grow its headcount to around 50 people in 2022. To accommodate this significantly increased headcount, EnteroBiotix will also be increasing its current office, lab, and warehouse space.
Dr James McIlroy, CEO at EnteroBiotix, said: “Our new facility and overall site expansion is another significant milestone on our mission to transform the lives of patients through our orally delivered medicinal products enhancing the gut microbiome. Offering best-in-class capabilities, it will support the high quality, safe and consistent manufacturing and quality control of both our own and partnered programmes. As we extend our capacity and team during this exciting phase, we are determined to change the standard of care for patients battling debilitating diseases, including cancer, associated with the microbiome.”
Rosemary Hill, Director at Strathclyde Business Park, said: “Strathclyde Business Park provides great access to a skilled local workforce and is Scotland’s leading business location. We are delighted that yet another high caliber company has significantly expanded its premises in one of Scotland’s most inspirational working environments. This is further testament to the outstanding quality of Scotland’s thriving life sciences ecosystem.”
EnteroBiotix’s approach is focused on enhancing the diversity of the microbiome to address debilitating diseases. Its product portfolio has potential applicability across multiple disease areas including immuno-oncology and diseases of the gut-liver-brain axis.
The new facility was designed and built by Cleanroom Construction Company. It is located on Western Campus, part of Strathclyde Business Park. Western Campus is owned by Industrials REIT.
--- ENDS ---
Media contacts:
EnteroBiotix
Dr James McIIroy, CEO
j.mcilroy@enterbiotix.com
Scius Communications
Katja Stout
+447789435990
katja@sciuscommunications.com
Daniel Gooch
+447747875479
dan@sciuscommunications.com
About EnteroBiotix
EnteroBiotix is a biopharmaceutical company developing novel medicinal products that enhance the gut microbiome and target multiple disease indications. Established in 2017, EnteroBiotix is headquartered in Glasgow, Scotland and operates research laboratories and GMP pharmaceutical manufacturing suites in Glasgow and Aberdeen. The company has raised around £18m in equity investment since incorporation, from investors including Thairm Bio, Scottish Enterprise, and Kineticos Life Sciences. The company also owns a subsidiary operation called Number 2, which ensures the security and quality of supply of microbiota from human donors. For more details see https://www.enterobiotix.com/ and https://www.linkedin.com/company/enterobiotix/.
